Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
We report a patient with a history of leukopenia who developed acute myeloid leukemia (AML) FAB M2 and was successfully treated with induction and consolidation chemotherapy. She relapsed 7 months after initial diagnosis. Peripheral blood cells at relapse showed a t(12;15)(p13;q13), which has not been previously described in de novo or relapsed AML.
Lim
S W
SW
Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, 90048, USA.
Falk
R E
RE
Look
R M
RM
Fuerst
M M
MM
Lawrence
G N
GN
Kusuanco
D A
DA
Giles
F J
FJ
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002881:Chromosomes, Human, Pair 12; D002884:Chromosomes, Human, Pair 15; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D012008:Recurrence; D014178:Translocation, Genetic
D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin